natgillin/translations-raw huggingface dataset:
• Water retention (which shows as puffy fingers or swollen ankles) Common side effects (likely to occur in fewer than 1 in 10 patients) include: In children 
• zadržavanje vode (očituje se oticanjem prstiju ili gležnjeva) Česte nuspojave (vjerojatnost javljanja u manje od 1 na 10 bolesnika) obuhvaćaju:
• For single use only. 
• Samo za jednokratnu primjenu.
• After starting somatropin treatment some patients may need to start thyroid hormone replacement. 
• Pojedini bolesnici nakon započinjanja liječenja somatropinom moraju započeti nadomjesnu terapiju hormonima štitnjače.
Cases of leukaemia (rare or very rare) have been reported in growth hormone deficient children treated with somatropin and included in the post-marketing experience. 
U djece s deficitom hormona rasta liječene somatotropinom zabilježeni su slučajevi leukemije (rijetko ili vrlo rijetko) i uključeni u iskustvo nakon stavljanja lijeka u promet.
Growth hormone deficiency Prader-Willi syndrome Turner syndrome 
Deficit hormona rasta Prader-Willijev sindrom Turnerov sindrom
• Store in the original package in order to protect from light. 
• Čuvati u originalnom pakiranju radi zaštite od svjetlosti.
10 A-6336 Langkampfen Austria 
Sandoz GmbH Biochemiestr. 10 A-6336 Langkampfen Austrija
• If you are receiving treatment with thyroid hormones it may become necessary to adjust your thyroid hormone dose. 
• Ako primate terapiju s hormonima štitnjače, možda ćete morati prilagoditi dozu hormona štitnjače.
How to inject Omnitrope 5 mg/ml 
Kako injicirati Omnitrope 5 mg/ml
Based on available literature, hypothalamic-pituitary-adrenal axis can be affected and needs to be re-assessed during growth hormone therapy in growth hormone deficient patients, who were previously not found to be deficient in this axis. 
Na temelju dostupne literature ustanovljeno je da tijekom terapije hormonom rasta funkcija osi hipotalamus-hipofiza-nadbubrežna žlijezda može biti zahvaćena, pa je potrebno ponovno procijeniti funkciju osi u bolesnika s manjkom hormona rasta u kojih prethodno nije ustanovljen poremećaj u toj osi.
The following is a general description of the administration process. 
U nastavku je naveden opći opis postupka primjene.
Pack sizes of 1, 5 and 10. 
Veličine pakovanja: 1, 5 i 10.
Use only with Omnitrope Pen 5. 
Koristiti samo uz Omnitrope Pen L.
If you forget to use Omnitrope 
Ako ste zaboravili primijeniti Omnitrope
If you stop using Omnitrope 
Ako prestanete primjenjivati Omnitrope
Somatropin 1.3 mg (4 IU)/ml in a vial. 
Somatropin 1,3 mg (4 IU)/ml u bočici.
Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms. 
Najčešći među tim drugim novotvorinama bili su intrakranijalni tumori, osobito meningeomi, u bolesnika liječenih zračenjem glave zbog prve novotvorine.
Dose recommendations in paediatric patients Indication mg/kg body weight dose per day mg/m² body surface area dose per day 
Preporučene doze u pedijatrijskih bolesnika Indikacija mg/kg tjelesne težine dnevna doza mg/m² tjelesne površine dnevna doza
The top of the vials should be wiped with an antiseptic solution to prevent contamination of the contents. 
Gornji dio bočica mora se obrisati antiseptičkom otopinom radi sprječavanja kontaminacije sadržaja.
Inject the solution by pushing the plunger all the way down gently. 
Injicirajte otopinu tako da polagano potisnete klip dolje do kraja.
This condition is reversed by somatropin. 
To je stanje reverzibilno uz somatropin.
- a pen needle for subcutaneous injection. 
- iglu za brizgalicu za potkožnu injekciju.
However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors.) 
Međutim, nema dokaza da je incidencija leukemije povećana u osoba bez predisponirajućih čimbenika koje primaju hormon rasta).
Your doctor should have already shown you how to use Omnitrope. 
Liječnik Vam je morao pokazati kako primjenjivati Omnitrope.
• Temporary reddening, itchiness or pain at the injection site 
• Privremeno crvenilo, svrbež ili bol na mjestu injiciranja.
For storage conditions of the in-use medicinal product, see section 6.3. 
Uvjete čuvanja lijeka u primjeni vidjeti u dijelu 6.3.
Clean the site of injection with an alcohol swab. 
Očistite mjesto injiciranja alkoholnom maramicom.
Omnitrope 5 mg/1.5 ml solution for injection: One ml contains 9 mg benzyl alcohol. 
Omnitrope 5 mg/1,5 ml otopina za injekciju: Jedan ml sadrži 9 mg benzilnog alkohola.
- Growth disturbance associated with chronic renal insufficiency. 
- Poremećaj rasta povezan s kroničnom insuficijencijom bubrega.
Long-term treatment of children with growth disturbance due to born small for gestational age System Organ 
Dugotrajno liječenje djece s poremećajem rasta jer su bila rođena mala za gestacijsku dob
In addition, patients already receiving glucocorticoid replacement therapy may need to have the dose of their replacement therapy adjusted, after somatropin treatment is initiated. 
Osim toga, u bolesnika koji već primaju nadomjesnu terapiju glukokortikoidima, dozu nadomjesne terapije možda će trebati prilagoditi nakon što se započne liječenje somatropinom.
Omnitrope has no or negligible influence on the ability to drive and use machines. 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Omnitrope ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
A decrease in peripheral vascular resistance may contribute to this effect. 
Tom učinku može pridonositi smanjenje perifernog vaskularnog otpora.
The following instructions explain how to inject Omnitrope yourself. 
U uputama u nastavku objašnjeno je kako ćete sami injicirati Omnitrope.
Powder and solvent for solution for injection (powder in a vial (1.3 mg), solvent in a vial (1 ml)). 
Prašak i otapalo za otopinu za injekciju (prašak u bočici (1,3 mg), otapalo u bočici (1 ml)).
How to inject Omnitrope 1.3 mg/ml 
Kako injicirati Omnitrope 1,3 mg/ml
Somatropin 5 mg (15 IU)/ml in a vial. 
Somatropin 5 mg (15 IU)/ml u bočici.
• Reddening, itchiness or pain at the injection site 
• crvenilo, svrbež ili bol na mjestu injiciranja
The reconstituted solution should be administered using sterile, disposable syringes. 
Pripremljena otopina se mora primijeniti pomoću sterilnih, jednokratnih štrcaljki.
Push the needle fitted to the syringe through the rubber membrane. 
Iglu pričvršćenu za štrcaljku uvedite kroz gumenu membranu.
The maintenance dose in these patients seldom exceeds 0.5 mg per day. 
Doza održavanja u ovih bolesnika rijetko prelazi 0,5 mg na dan.
If you have been treated with Omnitrope for growth hormone deficiency during childhood, your growth hormone status will be retested after completion of growth. 
Ako ste tijekom djetinjstva liječeni Omnitropeom zbog nedostatka hormona rasta, nakon završetka rasta ponovno će se ispitati stanje hormona rasta.
Unopened vial 
Neotvoreni uložak
- The active substance of Omnitrope is somatropin. 
- Djelatna tvar Omnitropea je somatropin.
• Store and transport refrigerated (2°C-8°C). 
• Čuvati i prevoziti na hladnom (2 °C-8 °C).
Long-term treatment of children with growth disturbance due to Turner syndrome System Organ 
Dugotrajno liječenje djece s poremećajem rasta zbog Turnerovog sindroma
Clean the injection site with an alcohol swab and administer Omnitrope by subcutaneous injection. 
Očistite mjesto injiciranja alkoholnom maramicom i primijenite Omnitrope u obliku supkutane injekcije.
1.5 ml of solution in a cartridge (colourless type I glass) with plunger on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side. 
1,5 ml otopine u ulošku (bezbojno staklo tip I) s klipom na jednoj strani (silikonizirani bromobutil), te diskom (bromobutil) i zatvaračem (aluminij) na drugoj strani.
Slipped capital femoral epiphysis and Legg-Calvé-Perthes disease have been reported in children treated with GH. 
Iskliznuće epifize glave femura i Legg-Calvé-Perthesova bolest zabilježeni su u djece liječene hormonom rasta.
1.5 ml of solution in a cartridge (colourless type I glass) with plunger and a blue ring (for Omnitrope 15 mg/1.5 ml solution for injection only) on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side. 
1,5 ml otopine u ulošku (bezbojno staklo tip I) s klipom na jednoj strani i plavim prstenom (samo za Omnitrope 15 mg/1,5 ml otopinu za injekciju) (silikonizirani bromobutil) te diskom (bromobutil) i zatvaračem (aluminij) na drugoj strani.
Chronic renal insufficiency Children/adolescents born small for gestational age (SGA) 
Kronična insuficijencija bubrega Djeca/adolescenti koji su rođeni mali za gestacijsku dob
- The residual solution, vials, and injection materials intended for single use must be discarded. 
- Ostatak otopine, bočice i jednokratni materijal za injiciranje morate baciti.
The clinical significance of this is unknown. 
Klinička značajnost tog nalaza nije poznata.
- Turn the vial and the syringe upside down in one hand. 
- Preokrenite bočicu i štrcaljku jednom rukom.
Children with growth hormone deficiency: 
Djeca s nedostatkom hormona rasta:
Children with hypopituitarism may experience fasting hypoglycaemia. 
U djece s hipopituitarizmom moguća je pojava hipoglikemije natašte.
Eliminate air bubbles if necessary. 
Istisnite mjehuriće zraka, ako postoje.
Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth. 
U bolesnika s deficijencijom hormona rasta koja je nastupila u djetinjstvu treba ponovno procijeniti kapacitet lučenja hormona rasta nakon završetka longitudinalnog rasta.
≥ 1/1,000 to 
≥ 1/1000 i
Carbohydrate metabolism 
Metabolizam ugljikohidrata
Some of the height gain obtained with treating short children/adolescents born SGA with growth hormone may be lost if treatment is stopped before final height is reached. 
Ako se liječenje niske djece/adolescenata rođenih malih za gestacijsku dob hormonom rasta prekine prije dostizanja konačne visine, dio visine postignut liječenjem može se izgubiti.
Prader-Willi syndrome 
Prader-Willijev sindrom
Adults with growth hormone deficiency: 
Odrasli s nedostatkom hormona rasta:
However, after subcutaneous administration of Omnitrope 15 mg/1.5 ml solution for injection, a half life of 2.76 hours is achieved. 
Međutim, nakon supkutane primjene Omnitrope 15 mg/1,5 ml otopine za injekciju postiže se poluvijek od 2,76 sata.
Long-term treatment of children with growth disturbance due to insufficient secretion of growth hormone 
Dugotrajno liječenje djece s poremećajem rasta zbog nedovoljnog lučenja hormona rasta
In SGA children/adolescents it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. 
U djece/adolescenata rođenih malih za gestacijsku dob preporučuje se prije započinjanja liječenja te nakon toga jednom godišnje izmjeriti vrijednosti inzulina i glukoze u krvi natašte.
The top of the vial and of the cartridge should be wiped with an antiseptic solution in order to prevent contamination of the contents. 
Gornji dio bočice i uloška mora se obrisati antiseptičkom otopinom radi sprječavanja kontaminacije sadržaja.
Somatropin has been reported to reduce serum cortisol levels, possibly by affecting carrier proteins or by increased hepatic clearance. 
Snižene razine kortizola u serumu Zabilježeno je da somatropin smanjuje vrijednosti kortizola u serumu, vjerojatno zbog utjecaja na prijenosne proteine ili zbog povećanja hepatičkog klirensa.
Do not use Omnitrope 
Nemojte primjenjivati Omnitrope
In studies with Omnitrope regarding subacute toxicity and local tolerance, no clinically relevant effects have been observed. 
Prilikom ispitivanja subakutne toksičnosti i lokalne podnošljivosti Omnitropea nisu opaženi klinički relevantni učinci.
However, after subcutaneous administration of Omnitrope powder and solvent for solution for injection, a half-life of 3 hours is achieved. 
Međutim, nakon supkutane primjene Omnitrope praška i otapala za otopinu za injekciju postiže se poluvijek od 3 sata.
- Hold the syringe with the needle in the vial pointing up and remove the syringe from the vial. 
- Štrcaljku s iglom u bočici držite usmjerenu prema gore i izvucite štrcaljku iz bočice.
Growth hormone deficient adult patients 
Nedostatak hormona rasta u odraslih bolesnika
STATEMENT OF ACTIVE SUBSTANCE Somatropin 6.7 mg (20 IU)/ml. 
Somatropin 6,7 mg (20 IU)/ml.
SPECIAL STORAGE CONDITIONS Store and transport refrigerated (2°C - 8°C). 
POSEBNE MJERE ČUVANJA Čuvati i prevoziti na hladnom (2 °C - 8 °C).
Children with Prader-Willi syndrome: 
Djeca s Prader-Willijevim sindromom:
Paraesthesia* Benign intracranial hypertension 
Poremećaji živčanog sustava parestezija* benigna intrakranijalna hipertenzija
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON LABEL 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU OZNAKA NA VANJSKOM PAKIRANJU
Long-term treatment of children with growth disturbance due to chronic renal insufficiency System Organ 
Dugotrajno liječenje djece s poremećajem rasta zbog kronične bubrežne insuficijencije
An increased chromosome fragility has been observed in one in vitro study on lymphocytes taken from patients after long term treatment with somatropin and following the addition of the radiomimetic drug bleomycin. 
U jednom in vitro ispitivanju provedenom na limfocitima bolesnika nakon dugotrajnog liječenja somatropinom i nakon dodavanja radiomimetičkog lijeka bleomicina opažena je povećana fragilnost kromosoma.
1 vial of 1 ml solvent 
1 bočica s 1 ml otapala
Do not use Omnitrope if you notice that the solution is cloudy. 
Ovaj lijek se ne smije upotrijebiti ako primijetite da je otopina mutna.
For guidance on dosing see adult section below. 
Za smjernice o doziranju, vidjeti niže dio koji se odnosi na odrasle.
1 cartridge for SurePal 5 
1 uložak za SurePal 5
The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency. 
Incidencija ovih nuspojava povezana je s primijenjenom dozom, dobi bolesnika i moguće je obrnuto povezana s dobi bolesnika u vrijeme nastanka deficita hormona rasta.
Subcutaneous use after reconstitution 
Potkožna primjena nakon pripreme
If your growth hormone deficiency starts during adult life you should start with 0.15-0.3 mg per day. 
Ako se deficit hormona rasta pojavi u odrasloj dobi, liječenje trebate započeti s dozom od 0,15-0,3 mg na dan.
If overt diabetes occurs, growth hormone should not be administered. 
U slučaju manifestnog dijabetesa, ne smije se primjenjivati hormon rasta.
The active substance of Omnitrope is somatropin. 
Djelatna tvar Omnitropea je somatropin.
Medical treatment for your kidney should be continued. 
Liječenje bubrega mora se nastaviti.
Inject the solvent slowly. 
Polagano injicirajte otapalo.
Pack sizes of 1 and 5. 
Veličine pakovanja: 1 i 5.
Clinical trials in children with chronic renal insufficiency 
Klinička ispitivanja u djece s kroničnom bubrežnom insuficijencijom
Very common side effects (likely to occur in more than 1 in 10 patients) include: In adults 
Vrlo česte nuspojave (vjerojatnost javljanja u više od 1 na 10 bolesnika) obuhvaćaju: U odraslih
For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin therapy is instituted. 
U bolesnika sa šećernom bolešću će možda biti potrebno prilagoditi dozu inzulina nakon uvođenja terapije somatropinom.
- Inspect the reconstituted solution visually prior to administration. 
- Prije primjene vizualno provjerite rekonstituiranu otopinu.
When treatment with somatropin is started this deficit is rapidly corrected. 
Taj se deficit ispravlja brzo nakon početka liječenja somatropinom.
Omnitrope 5 mg/ml is supplied in a vial containing the active substance as a powder and the solvent filled in a cartridge. 
Omnitrope 5 mg/ml se isporučuje u bočici koja sadrži djelatnu tvar u obliku praška i s otapalom u ulošku.
However, after subcutaneous administration of Omnitrope 5 mg/1.5 ml, Omnitrope 10 mg/1.5 ml solution for injection, a half-life of 3 hours is achieved. 
Međutim, nakon supkutane primjene Omnitrope 5 mg/1,5 ml, Omnitrope 10 mg/1,5 ml otopine za injekciju postiže se poluvijek od 3 sata.
Patients with growth hormone deficiency are characterised by extracellular volume deficit. 
U bolesnika s nedostatkom hormona rasta prisutan je deficit izvanstaničnog volumena.
Long-term treatment and improvement of body composition of children with growth disturbance due to Prader-Willi syndrome 
Dugotrajno liječenje i poboljšanje sastava tijela kod djece s poremećajem rasta zbog Prader
Common to < 1/10 
Rijetko i < 1/1000
- The solution should be clear after removal from the refrigerator. 
- Kada je izvadite iz hladnjaka, otopina mora biti bistra.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg per day. 
U odraslih s deficijencijom hormona rasta nastalom u odrasloj dobi, terapiju treba započeti malom dozom, od 0,15 - 0,3 mg na dan.
The solution is for single use only. 
Otopina je namijenjena samo za jednokratnu primjenu.
Bring the syringe to the correct dose needed. 
Da biste podesili brizgalicu, odaberite odgovarajuću dozu.
- The contents must be clear and colourless. 
- Sadržaj mora biti bistar i bezbojan.
All patients with PWS should be evaluated for sleep apnoea and monitored if sleep apnoea is suspected.Patients should be monitored for signs of respiratory infections, which should be diagnosed as early as possible and treated aggressively. 
U bolesnika se moraju pratiti eventualni znakovi respiratornih infekcija, a infekcija se mora što prije dijagnosticirati i agresivno liječiti.
- a vial with solvent (liquid) for Omnitrope 1.3 mg/ml. 
- bočicu s otapalom (tekućinom) za Omnitrope 1,3 mg/ml.
Store in the original pen in order to protect from light. 
Čuvati u originalnoj brizgalici radi zaštite od svjetlosti.
How to inject Omnitrope 
Kako injicirati Omnitrope
Pack size of 1. 
Veličina pakovanja: 1.
Shelf life after first use 
Rok valjanosti nakon prve primjene
Store and transport refrigerated (2°C - 8°C). 
Čuvati i prevoziti na hladnom (2 °C - 8 °C).
Musculoskeletal stiffness* 
mišićno-koštana ukočenost*
Rare side effects (likely to occur in fewer than 1 in 1,000 patients) include: In children 
Rijetke nuspojave (vjerojatnost javljanja u manje od 1 na 1000 bolesnika) obuhvaćaju: U djece
Reconstituting Omnitrope - Remove the protective caps from the two vials in the box. 
- Uklonite zaštitne zatvarače s dviju bočica iz kutije.
As kidneys lose their ability to function normally, this can affect growth. 
Smanjenje normalne funkcije bubrega može utjecati na rast.
It has to be administered using sterile, disposable pen needles. 
Mora se primjenjivati pomoću sterilnih jednokratnih igli za brizgalicu.
It also helps your fat and muscle tissues to develop in the right amounts. 
Pospješuje i odgovarajući razvoj masnog i mišićnog tkiva.
Intracranial tumours must be inactive and anti-tumour therapy must be completed prior to starting GH therapy. 
Prije započinjanja terapije hormonom rasta intrakranijalni tumori moraju biti neaktivni, a antitumorska terapija mora biti završena.
Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope cartridges and the pen from the physician or other suitable qualified health professionals. 
Bolesnici i osobe koje se brinu za bolesnike moraju biti odgovarajuće educirani i od strane liječnika ili drugog kvalificiranog zdravstvenog osoblja dobiti upute za pravilno korištenje Omnitrope uložaka i brizgalice.
Children with Prader-Willi syndrome 
Djeca s Prader-Willijevim sindromom
If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse. 
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku ili medicinskoj sestri.
Clinical response and side effects may also be used as guidance for dose titration. 
Za titraciju doze mogu se kao smjernice koristiti i klinički odgovor i nuspojave.
1 vial of 5 mg powder 1 cartridge of 1 ml solvent 5 vials of 5 mg powder 5 cartridges of 1 ml solvent 
1 bočica s 5 mg praška 1 uložak s 1 ml otapala 5 bočica s 5 mg praška 5 uložaka s 1 ml otapala
Signs of scoliosis should be monitored during treatment. 
Tijekom liječenja potrebno je pratiti pojavu znakova skolioze.
Children with Turner syndrome: 0.045-0.050 mg/kg body weight per day or 1.4 mg/m2 body surface area per day. 
Djeca s Turnerovim sindromom: 0,045-0,050 mg/kg tjelesne težine na dan ili 1,4 mg/m2 površine tijela na dan.
For instructions for use and handling see section 6.6. 
Za uputu o primjeni i rukovanju, vidjeti dio 6.6. 4.3 Kontraindikacije
Higher doses may be needed if growth velocity is too low. 
Ako je brzina rasta premala, mogu biti potrebne i veće doze.
The following instructions explain how to inject Omnitrope 1.3 mg/ml yourself. 
U uputama u nastavku objašnjeno je kako ćete sami injicirati Omnitrope 1,3 mg/ml.
The following instructions explain how to inject Omnitrope 5 mg/ml yourself. 
U uputama u nastavku objašnjeno je kako ćete sami injicirati Omnitrope 5 mg/ml.
Powder in a vial (type I glass) with a stopper (fluor-resin laminated butyl rubber), a strip (aluminium) and a cap (green polypropylene flip-off), and 1 ml of solvent in a cartridge (type I glass) with a stopper (fluor-resin laminated chlorobutyl elastomer), a strip (lacquered aluminium) and a cap (white polypropylene flip-off). 
(aluminij) i zatvarač (ljubičasti polipropilenski „flip-off“), te 1 ml otapala u bočici (staklo tip I) s čepom (klorobutilni elastomer laminiran smolom fluora), dvoslojnica/strip (lakirani aluminij) i zatvarač (bijeli polipropilenski „flip-off“).
One vial contains 1.3 mg (corresponding to 4 IU) of somatropin after reconstitution with 1 ml solvent. 
Jedna bočica sadrži 1,3 mg (što odgovara vrijednosti od 4 IU) somatropina nakon pripreme s 1 ml otapala.
Conversely, if a woman on somatropin discontinues oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects (see section 4.5). 
dozu lijeka somatropinom možda će biti potrebno sniziti kako bi se izbjegao višak hormona rasta i/ili nastanak nuspojava (vidjeti dio 4.5).
5 cartridges for SurePal 5 10 cartridges for SurePal 5 
5 uložaka za SurePal 5 10 uložaka za SurePal 5
In general, administration of somatropin to growth hormone deficient patients results in reduction in serum LDL and apolipoprotein B. A reduction in serum total cholesterol may also be observed. 
Primjena somatropina u bolesnika s deficitom hormona rasta općenito smanjuje LDL i apolipoprotein B u serumu.
Omnitrope 5 mg/1.5 ml solution for injection 2 years. 
Omnitrope 5 mg/1,5 ml otopina za injekciju 2 godine.
STATEMENT OF ACTIVE SUBSTANCE Somatropin 10 mg (30 IU)/ml. 
Somatropin 10 mg (30 IU)/ml.
The maintenance dose rarely exceeds 1.0 mg per day. 
Dnevna doza održavanja rijetko prekoračuje 1,0 mg na dan.
Injecting Omnitrope - With a cleansing swab, disinfect the rubber membrane of the cartridge. 
Injiciranje Omnitropea - Tupferom za čišćenje, dezinficirajte gumenu membranu uloška.
- Take the vial with solvent and the sterile, disposable syringe (e.g. 2 ml syringe) and needle (e.g. 0.33 mm x 12.7 mm). 
Pomoću sterilne, jednokratne štrcaljke (npr. štrcaljke od 2 ml) i igle (npr. 0,33 mm x 12,7 mm)
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS OMNITROPE CARTRIDGE LABEL 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE OZNAKA NA ULOŠKU LIJEKA OMNITROPE
Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope vials, the cartridges with solvent, the transfer set and the pen from the physician or other suitable qualified health professionals. 
Bolesnici i osobe koje se brinu za bolesnike moraju biti odgovarajuće educirani i od strane liječnika ili drugog kvalificiranog zdravstvenog osoblja dobiti upute za pravilno korištenje Omnitrope bočica, uložaka s otapalom, kompleta za prijenos i brizgalice.